Clinical and laboratory changes produced by piroxicam in rheumatoid arthritis.

Abstract	Twenty-five patients with active rheumatoid arthritis received treatment with piroxicam during 12 weeks in an open, non-comparative trial. In addition to improvement of clinical parameters, a significant diminution of the erythrocyte sedimentation rate and a decrease in rheumatoid factor titers was noted in both serum and synovial fluid.
Authors	R C De Zubiria, A Charria, D Lobo Guerrero
Journal	European journal of rheumatology and inflammation (Eur J Rheumatol Inflamm) Vol. 6 Issue 1 Pg. 56-62 ( 1983) ISSN: 0140-1610 [Print] England
PMID	6861814 (Publication Type: Journal Article)
Chemical References	Anti-Inflammatory Agents Thiazines Piroxicam Rheumatoid Factor
Topics	Adult Anti-Inflammatory Agents (blood, metabolism, therapeutic use) Arthritis, Rheumatoid (drug therapy) Female Humans Male Middle Aged Pain (drug therapy) Piroxicam Rheumatoid Factor (metabolism) Synovial Fluid (metabolism) Thiazines (blood, metabolism, therapeutic use) Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!